LIFTT has announced a €1.7 million investment in Lipogems, a pioneering Italian company in regenerative medicine, aiming to revolutionize osteoarthritis treatment.

Target Information

Lipogems is a multinational company based in Milan, operating in the regenerative medicine sector and present in 28 countries. With the status of an innovative SME, Lipogems has patented a groundbreaking device and technique that significantly advances osteoarthritis treatment, addressing a major disabling disease affecting over 250 million people globally each year.

The Lipogems technology establishes a new standard in orthopedics, attracting interest from major players in various surgical specialties that currently lack definitive solutions to alter disease progression. The financial market for osteoarthritis therapies was valued at approximately $7 billion in 2020 and is projected to reach $16 billion by 2030.

Industry Overview

The regenerative medicine industry is evolving rapidly, with new technologies emerging to treat chronic conditions like osteoarthritis. In Italy, where Lipogems is headquartered, the healthcare system is adapting to incorpor